| Developers: | Medtronic |
| Branches: | Pharmaceuticals, Medicine, Healthcare |
2022: Onyx Frontier DES Stents Launch
On August 25, 2022, Medtronic announced the launch of its new Onyx Frontier DES coronary stent, which is used to treat patients with coronary heart disease caused by a build-up of plaques on the inner surface of the coronary arteries.
The most significant new technologies in Onyx Frontier DES, according to the developers, include an innovative two-layer balloon, a lower intersection profile, and increased catheter flexibility, allowing a 16% improvement in delivery efficiency over the previous generation of Resolute Onyx DES without compromising radial strength. In addition to the advanced delivery system, Onyx Frontier offers a wide size matrix for treating patients from 2.0 mm to 5.0 mm in diameter, and 4.50-5.00 mm sizes can be expanded to 6.00 mm - specifically to support super-large vessels. Onyx Frontier inherited the same clinical data and indications as Resolute Onyx, including approval for the treatment of bifurcation lesions, left-sided PCI, and the delivery of dual antiplatelet therapy (DAPT) for one month in patients at high risk of bleeding.
 | The launch of Onyx Frontier DES demonstrates our commitment to the interests of interventional cardiologists by providing best-in-class products, "said Jason Weidman, senior vice president and president of the Coronary and Renal Denervation Division, which is part of Medtronic's cardiovascular product portfolio. After entering the US market, we are pleased to provide hospitals in Western Europe and around the world with Onyx Frontier DES, which has been carefully designed to meet the needs of physicians. This launch further reinforces Medtronic's goal of developing the unusual, and we continue to eagerly strive for innovation every day.[1] |  |
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |